The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monte Rosa Therapeutics with a $16.00 average price target, a 74.7% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $14.00 price target.